Rachel’s practice focuses on intellectual property litigation, with an emphasis on patent litigation in federal district court and before the US Patent and Trademark Office. Her practice is primarily within the life science space.
Liquidia Technologies Prevails in High Blood Pressure Drug Patent Litigation
June 27, 2024
Cooley successfully defeated an inter partes review on behalf of Liquidia Technologies, a biopharmaceutical company focused on the development and commercialization of products to treat pulmonary hypertension, in United Therapeutics Corp. v. Liquidia Technologies Inc., case number 22-2133, in the US Court of Appeals for the Federal Circuit, relating to Liquidia’s high blood pressure drug patent.
Cooley Defeats Preliminary Injunction for Liquidia in Litigation With United Therapeutics
June 3, 2024
Cooley successfully defeated a preliminary injunction filed by United Therapeutics that sought to block the launch of client Liquidia’s Yutrepia (treprostinil) inhalation powder for treatment of pulmonary hypertension associated with interstitial lung disease.